Search results
Results From The WOW.Com Content Network
In this article we will take a look at whether hedge funds think Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a good investment right now. We check hedge fund and billionaire investor sentiment ...
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem.
Even though the markets took a beating over the past week and biotech stocks experienced a broader industry sell-off, one stock in this space stood out as the clear winner on the market on Monday.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. It was another ...
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
"Lowering drug prices is a focus area for both Republicans and Democrats, and Chinese CDMOs [manufacturers] such as Wuxi Group play a key role as it helps the US pharma cut costs by 30-60%.
Corporate news. Some of the biggest stock movers on Thursday include: Oualcomm topped earnings estimates on strong smartphone demand, but its licensing revenues missed forecasts. Shares shed 3.72%.